These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 2272033)
1. Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer. Price LA; Hill BT Cancer Treat Rev; 1990 Sep; 17(2-3):191-6. PubMed ID: 2272033 [No Abstract] [Full Text] [Related]
2. [Treatment of metastatic breast cancer]. Yahalom J; Biran S; Sulkes A Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868 [No Abstract] [Full Text] [Related]
3. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706 [TBL] [Abstract][Full Text] [Related]
4. Five-drug therapy in advanced breast cancer: factors influencing toxicity and response. Davis HL; Ramirez G; Ellerby RA; Ansfield FJ Cancer; 1974 Aug; 34(2):239-45. PubMed ID: 4852055 [No Abstract] [Full Text] [Related]
5. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer. Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience. Rivkin SE; Glucksberg H; Foulkes M Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770 [No Abstract] [Full Text] [Related]
7. High-dose versus low-dose CMFP regimen in advanced breast cancer. Kumar A; Khanna NN; Pant GC; Khanna S J Surg Oncol; 1984 Apr; 25(4):300-2. PubMed ID: 6371385 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules]. Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849 [No Abstract] [Full Text] [Related]
9. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone. Parvinen LM; Numminen S Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135 [TBL] [Abstract][Full Text] [Related]
10. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
11. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. Goodyear M J Clin Oncol; 1986 Mar; 4(3):442-4. PubMed ID: 3512787 [No Abstract] [Full Text] [Related]
12. The importance of dose intensity in chemotherapy of metastatic breast cancer. Hryniuk W; Bush H J Clin Oncol; 1984 Nov; 2(11):1281-8. PubMed ID: 6387060 [No Abstract] [Full Text] [Related]
13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
14. The problem of local control in patients with advance breast cancer--a combined modality approach. Boyages J Australas Radiol; 1986 Feb; 30(1):60-2. PubMed ID: 3755336 [No Abstract] [Full Text] [Related]
15. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133 [TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion. Lokich J; Bern M; Anderson N; Wallach S; Moore C; Beauchamp K; Williams D Cancer; 1989 Mar; 63(5):822-4. PubMed ID: 2914289 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
18. Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP). Guglielmi C; Amadori S; Anselmo AP; Baroni CD; Biagini C; Cimino G; Papa G; Mandelli F Cancer Invest; 1987; 5(3):159-69. PubMed ID: 3651863 [TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]